POD levodopa intranasal (INP-103)
/ Impel Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 31, 2018
Impel NeuroPharma announces initiation of phase IIa study of INP103 in Parkinson's disease OFF episodes
(PRNewswire)
- "Impel NeuroPharma…announced the initiation of a Phase IIa study designed to explore the safety and pharmacodynamic effect of intranasal levodopa in Parkinson's disease (PD) patients during an OFF episode compared to placebo….reporting topline results from this study in the second half of 2018."
P2a data • Trial initiation date • CNS Disorders • Parkinson's Disease
June 18, 2019
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a; N=32; Completed; Sponsor: Impel NeuroPharma Inc.; Recruiting ➔ Completed
Clinical • Trial completion
March 19, 2019
THOR 201: Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
(clinicaltrials.gov)
- P2a; N=32; Recruiting; Sponsor: Impel NeuroPharma Inc.; N=24 ➔ 32
Clinical • Enrollment change
1 to 3
Of
3
Go to page
1